Endostar Combined with Gemcitabine and Cisplatin Chemotherapy for Patients with Metastatic Nasopharyngeal Carcinoma: an Update
| Autor: | Yongfeng Piao, Feng Jiang, Xiaozhong Chen, Qi-Feng Jin, Ting Jin |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2018 |
| Předmět: |
0301 basic medicine
Oncology Cancer Research medicine.medical_specialty Original article medicine.medical_treatment Neutropenia lcsh:RC254-282 03 medical and health sciences 0302 clinical medicine Internal medicine medicine Adverse effect Cisplatin Chemotherapy Leukopenia business.industry medicine.disease lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens Gemcitabine Regimen 030104 developmental biology Nasopharyngeal carcinoma 030220 oncology & carcinogenesis medicine.symptom business medicine.drug |
| Zdroj: | Translational Oncology, Vol 11, Iss 2, Pp 286-291 (2018) Translational Oncology |
| ISSN: | 1936-5233 |
| Popis: | OBJECTIVE: A previous phase-2 trial to assess the addition of Endostar to gemcitabine and cisplatin (GC) chemotherapy showed that it improves prognosis in metastatic nasopharyngeal carcinoma (M-NPC) but the study cohort was small. We wished to update that phase-2 trial by enrolling an additional 44 patients and to assess the benefit of Endostar+GC chemotherapy. METHODS: An analysis of 72 M-NPC patients treated between July 2010 and November 2016 was done. The treatment regimen was a combination of gemcitabine (1,000 mg/m 2 ) on days 1 and 8, cisplatin (80 mg/m 2 ) on day 1, and Endostar (15 mg/day) from day 1 to day 14 of a 21-day cycle for ≥2 cycles. The acute toxic effects and therapeutic efficacy were analyzed. RESULTS: The response rate was 77.8%. The median progression-free and overall survivals were 12 and 19.5 months, respectively. A total of 329 cycles of GC and 288 cycles of Endostar were delivered to 72 patients, with the median number of four (range, 2–10) cycles administered per patient. The main grade-3/4 hematologic toxicities were leukopenia (54.1%) and neutropenia (59.8%). The number of non-hematologic adverse events was minimal. The regimen was well-tolerated. CONCLUSIONS: Endostar+GC chemotherapy is an effective, well-tolerated regimen for M-NPC. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|